Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LESSINA-21 vs ALYACEN 1/35
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Suppresses gonadotropin release (FSH, LH) from pituitary, inhibiting ovulation. Causes cervical mucus thickening and endometrial alterations, impeding sperm penetration and implantation.
Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.
Prevention of pregnancy (FDA-approved)
Prevention of pregnancy
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days placebo or no tablets.
One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.
17-21 hours (terminal elimination half-life; clinical significance: allows once-daily dosing, but missed doses increase risk of ovulation)
Norethindrone: 8-11 hours (terminal); ethinyl estradiol: 10-20 hours (terminal). The half-life supports once-daily dosing for oral contraceptive efficacy.
Ethinyl estradiol: primarily metabolized by CYP3A4, undergoes first-pass metabolism in gut wall and liver. Levonorgestrel: metabolized via reduction and conjugation, partially involving CYP3A4.
Ethinyl estradiol: primarily hepatic via CYP3A4; norethindrone: hepatic reduction and sulfate conjugation.
Renal (70% as unchanged drug and metabolites), fecal (30% as metabolites)
Renal excretion of metabolites (primarily ethinyl estradiol and norethindrone conjugates) accounts for approximately 50-60% of elimination; fecal excretion accounts for 30-40%. Unchanged drug excretion is minimal (<5%).
98-99% (albumin and sex hormone-binding globulin, SHBG)
Norethindrone: 61% bound to albumin and SHBG; ethinyl estradiol: 97-98% bound to albumin.
2-4 L/kg (extensive distribution into tissues, reflecting lipophilicity and binding to steroid receptors)
Norethindrone: 3.8-4.5 L/kg; ethinyl estradiol: 2.0-4.0 L/kg. Large Vd indicates extensive tissue distribution.
Oral: 88% (high bioavailability due to extensive absorption and minimal first-pass metabolism)
Oral: Norethindrone ~64%, ethinyl estradiol ~38-48% (due to first-pass metabolism).
No dose adjustment required for mild to moderate renal impairment. Insufficient data for severe impairment; use with caution.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure due to potential fluid retention and electrolyte disturbances.
Contraindicated in acute hepatitis, severe decompensated cirrhosis (Child-Pugh C), or liver tumors. For mild (Child-Pugh A) to moderate (Child-Pugh B) impairment, use only if benefits outweigh risks; monitor liver function.
Contraindicated in patients with hepatic impairment, including Child-Pugh class B or C, due to impaired metabolism of estrogen and progestin. Not recommended in patients with active liver disease or history of liver tumors.
Use only after menarche. Same dosing as adults (0.1 mg/0.02 mg daily for 21 days) for adolescents aged 12-17 years. Safety and efficacy not established in premenarchal girls.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults. Safety and efficacy established for contraception; weight-based dosing not applicable.
Not indicated for postmenopausal women. No specific geriatric dosing; consider increased risk of thromboembolic events and cardiovascular disease in women over 35 who smoke.
Not indicated for use after menopause due to lack of benefit and increased risks (e.g., cardiovascular, thromboembolic events). If used, monitor for fluid retention, hypertension, and glucose intolerance.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age (especially >35 years) and with number of cigarettes smoked. Women who smoke and use OCs should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Thrombotic disorders (venous thromboembolism, arterial thromboembolism, stroke, myocardial infarction) - discontinue if signs occur,Increased risk of myocardial infarction and stroke, especially in smokers >35 years,Hepatic neoplasia (benign/malignant) - discontinue if jaundice or hepatic adenoma develops,Hypertension - monitor blood pressure; discontinue if hypertension develops,Gallbladder disease,Carbohydrate/lipid metabolism effects,Headache - evaluate if new/worsening migraine,Bleeding irregularities (breakthrough bleeding, amenorrhea),Ocular lesions (retinal thrombosis) - discontinue if unexplained vision loss,Depression - discontinue if severe,Reduce efficacy with certain drugs (e.g., anticonvulsants, antibiotics)
Thrombotic disorders (e.g., DVT, PE, stroke, MI),Cerebrovascular disease,Hepatic neoplasia,Gallbladder disease,Hypertension,Carbohydrate and lipid effects,Ocular lesions,Hereditary angioedema,Chloasma,Menstrual irregularities,Pregnancy exclusion prior to initiation
Known or suspected pregnancy,Current or past history of thromboembolic disorders (e.g., DVT, PE),Cerebrovascular or coronary artery disease (current or history),Known thrombophilic conditions (e.g., Factor V Leiden, prothrombin mutation, protein S/C deficiency),Uncontrolled hypertension (BP ≥160/100 mm Hg),Diabetes with vascular involvement,Headaches with focal neurological symptoms (e.g., migraine with aura, age >35),Major surgery with prolonged immobilization,Known or suspected breast carcinoma or other estrogen-sensitive neoplasia,Hepatic adenoma or carcinoma, active liver disease, or impaired liver function,Undiagnosed abnormal uterine bleeding,Cigarette smoking in women >35 years,Hypersensitivity to any component
Venous or arterial thrombotic/thromboembolic disease (current or history),Cerebrovascular disease,Coronary artery disease,Known or suspected breast cancer,Endometrial or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component,Smoking in women over 35
Avoid grapefruit and grapefruit juice as they may increase ethinyl estradiol levels. No other significant food interactions. St. John's wort (herbal supplement) reduces contraceptive efficacy.
No significant food interactions. Grapefruit juice may increase estrogen levels, but clinically not a concern. Avoid excessive alcohol, which may impair liver function and increase estrogen exposure. Maintain a healthy diet, as weight gain is possible.
FDA Pregnancy Category X. First trimester: oral contraceptive use is associated with a slight increase in cardiovascular defects and limb reduction defects, though absolute risk is low. Second and third trimesters: no increased risk of major malformations; however, exposure may increase risk of neonatal jaundice, cholestasis, and transient hormonal effects. Discontinue if pregnancy is suspected.
Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including cardiovascular defects and limb reduction defects. Second/third trimesters: Potential for urogenital abnormalities and feminization of male fetus. Exposure is associated with subsequent development of clear cell adenocarcinoma of vagina/cervix in female offspring (DES-related).
Small amounts of ethinyl estradiol and levonorgestrel are excreted in breast milk (M/P ratio not determined). May reduce milk production and composition. Use is generally not recommended during breastfeeding; alternative contraception should be considered.
Small amounts of contraceptive steroids and/or metabolites have been identified in breast milk. M/P ratio: Not specifically determined for this combination; ethinyl estradiol M/P ratio ~0.02-0.04. Use may reduce milk production and quality. Breastfeeding not recommended during use. Alternative contraception advised.
Contraindicated in pregnancy; no dose adjustments are applicable. Discontinue use immediately if pregnancy is confirmed.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue medication immediately upon pregnancy detection.
Lessina-21 is a low-dose combination oral contraceptive containing 0.1 mg levonorgestrel and 0.02 mg ethinyl estradiol. Administer on day 1 of menstrual period or first Sunday after onset. Use backup contraception for first 7 days if starting after day 5. Missed pill management: if one pill missed, take as soon as remembered; if two pills missed, take two pills on two consecutive days. CYP34A inducers (e.g., rifampin, St. John's wort) reduce efficacy; consider alternative contraception. Monitor for hypertension, thromboembolism, and migraine with aura. Eating grapefruit may increase ethinyl estradiol levels. Avoid in patients with migraine with aura, history of VTE, or breast cancer.
ALYACEN 1/35 is a combination oral contraceptive containing ethinyl estradiol 35 mcg and norgestimate 1 mg. It is indicated for the prevention of pregnancy and for the treatment of moderate acne vulgaris in females ≥15 years of age who desire an oral contraceptive. Monitor for thromboembolic events, especially in smokers over 35 or those with migraine with aura. Use with caution in patients with liver impairment or history of cholestatic jaundice. The pill-free interval should not exceed 7 days; missed pills increase ovulation risk. Consider non-hormonal backup if vomiting or diarrhea occurs within 4 hours of dosing.
Take one pill at the same time every day. Do not skip pills.,Start your pack on the first day of your period or the first Sunday after your period starts.,If you miss one pill, take it as soon as you remember. If you miss two pills, take two pills for two days and use a backup method for 7 days.,Lessina-21 does not protect against STIs; use condoms.,Common side effects include nausea, headache, and breast tenderness; these often improve after 3 months.,Smoking increases risk of serious cardiovascular side effects; avoid smoking, especially if over 35 years old.,Call your doctor if you have leg pain, chest pain, shortness of breath, or severe headaches.
Take one tablet daily at the same time each day; do not skip doses.,Use an additional non-hormonal contraceptive (e.g., condoms) if you miss a pill, have vomiting, or diarrhea.,Smoking while on this pill increases the risk of blood clots and stroke, especially if you are over 35.,Contact your healthcare provider immediately if you have chest pain, leg pain/swelling, sudden vision changes, or severe headache.,This medication does not protect against HIV or other sexually transmitted infections.,Store at room temperature, away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LESSINA-21 vs ALYACEN 1/35, answered by our medical review team.
LESSINA-21 is a Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Suppresses gonadotropin release (FSH, LH) from pituitary, inhibiting ovulation. Causes cervical mucus thickening and endometrial alterations, impeding sperm penetration and implantation.. ALYACEN 1/35 is a Oral Contraceptive that works by Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LESSINA-21 and ALYACEN 1/35 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LESSINA-21 is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days placebo or no tablets.. The standard adult dose of ALYACEN 1/35 is: One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LESSINA-21 and ALYACEN 1/35 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LESSINA-21 is classified as Category C. FDA Pregnancy Category X. First trimester: oral contraceptive use is associated with a slight increase in cardiovascular defects and limb reduction defects, though absolute risk is. ALYACEN 1/35 is classified as Category C. Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.